Feedback / Questions
DVX201 - Deverra Therapeutics
https://www.prnewswire.com/news-releases/coeptis-therapeutics-signs-agreement-to-acquire-allogeneic-immuno-oncology-nk-platform-in-phase-1-clinical-trials-from-deverra-therapeutics-301799765.html
Apr 18, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next